Pharmaceutical Research and Manufacturers of America (PhRMA) expressed “serious concerns” with the federal government’s opposition to Johnson & Johnson’s (J&J’s) [...] …
Blog Posts
The head of an influential 340B hospital advocacy group claimed “victory” in the recent fight against Johnson & Johnson’s (J&J) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
Understanding Provider Panels
Provider panels are lists used by 340B Third-Party Administrators (TPAs) to determine which providers’ claims are 340B eligible. At a minimum, a provider panel should include:
- Provider’s eligible
Editor’s Note: An earlier version of this story incorrectly suggested that an Oct. 4 update to 340B ESP’s terms of [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Two community health centers urged a federal appeals court to overturn the dismissal of their 340B antitrust lawsuit, arguing in [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Federally qualified health centers (FQHCs) appear to use their 340B program savings to enhance safety-net care, according to a new [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The leader of a right-leaning think tank that’s received funding from the drug industry criticized pushback that led Johnson & [...] …